Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 11, 2019 - Issue
Submit an article Journal homepage
118
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons

Gabriel Tremblay1 Purple Squirrel Economics, New York, NY, USACorrespondence[email protected]
,
Tracy Westley1 Purple Squirrel Economics, New York, NY, USA
,
Joseph C Cappelleri2 Pfizer Inc, New York, NY, USA
,
Bhakti Arondekar2 Pfizer Inc, New York, NY, USA
,
Geoffrey Chan2 Pfizer Inc, New York, NY, USA
,
Timothy J Bell2 Pfizer Inc, New York, NY, USA
&
Andrew Briggs3 William R Lindsay Chair of Health Economics, Health Economics and Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
 show all
Pages 551-565 | Published online: 06 Sep 2019

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.